# OnCo record seamless-adaptive (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/seamless-adaptive/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "seamless-adaptive" ;
  schema:name "Seamless, adaptive and Bayesian trial designs"@en ;
  schema:alternateName "seamless"@en, "seamless phase 2/3"@en, "seamless phase 1/2"@en, "phase 1/2"@en, "phase 2/3"@en, "adaptive design"@en, "adaptive trial"@en, "adaptive randomisation"@en, "response-adaptive randomisation"@en, "Bayesian"@en, "Bayesian adaptive"@en, "Bayesian design"@en, "I-SPY 2"@en, "I-SPY"@en, "master protocol"@en, "sample size re-estimation"@en, "adaptive enrichment"@en, "biomarker-selected"@en, "biomarker-enriched"@en, "all-comers"@en, "unselected"@en, "unselected population"@en, "adaptive designs"@en, "master protocols"@en, "all-comer"@en, "unselected populations"@en ;
  schema:description "Trial designs that change as data come in: merging phases so successful drugs move forward without pause, dropping arms or doses that are not working, adding new ones, and shifting randomisation toward what seems to help. Faster and more efficient, but they need careful statistics to stay honest."@en ;
  schema:url <https://onco.cc/terms/seamless-adaptive/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Adaptive_design_(medicine)> ;
  schema:citation <https://en.wikipedia.org/wiki/Adaptive_design_(medicine)>, <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry> ;
  onco:related <https://onco.cc/terms/basket-umbrella-platform/>, <https://onco.cc/terms/interim-analysis/>, <https://onco.cc/terms/first-in-human/>, <https://onco.cc/terms/basket-trial/>, <https://onco.cc/terms/umbrella-trial/>, <https://onco.cc/terms/response-adaptive-randomisation/>, <https://onco.cc/terms/bayesian-trial-design/>, <https://onco.cc/terms/sample-size-re-estimation/>, <https://onco.cc/terms/smart-design/>, <https://onco.cc/terms/biomarker-stratified-design/>, <https://onco.cc/terms/pragmatic-trial/>, <https://onco.cc/terms/registry-based-trial/>, <https://onco.cc/terms/decentralised-trial/>, <https://onco.cc/terms/n-of-1-trial/>, <https://onco.cc/terms/cluster-randomised-trial/>, <https://onco.cc/terms/stepped-wedge-design/>, <https://onco.cc/terms/non-inferiority-margin/>, <https://onco.cc/terms/stratified-randomisation/>, <https://onco.cc/terms/group-sequential-design/>, <https://onco.cc/terms/dose-escalation-design/>, <https://onco.cc/terms/data-monitoring-committee/>, <https://onco.cc/terms/estimand/>, <https://onco.cc/terms/trial-failure-modes/>, <https://onco.cc/terms/window-of-opportunity-trial/>, <https://onco.cc/terms/master-protocol/> ;
  onco:sections <https://onco.cc/fronts/drug-discovery/> ;
  onco:technologies <https://onco.cc/technologies/digital-twins-trials/>, <https://onco.cc/technologies/n-of-1-platforms/> ;
  onco:trials <https://onco.cc/trials/stampede/>, <https://onco.cc/trials/nrg-hn002-hn005/>, <https://onco.cc/trials/rejoice-ovarian01/>, <https://onco.cc/trials/myelomatch/>, <https://onco.cc/trials/pediatric-match/>, <https://onco.cc/trials/aspen-06/> .